Intelligent Investor

Neurotech International Limited (ASX: NTI) - Share Price and Research

Current share price for NTI : $0.096 0.001 (1.05%)

Neurotech International Limited is a medical device and solutions company conducting clinical studies to assess the neuro-protective, anti-inflammatory and neuro-modulatory activities of our proprietary NTI/Dolce cannabis strains. NTI is currently utilising NTI164 in a study to treat paediatric Autism Spectrum Disorder (ASD), an ASX-listed company, and commercialising Mente, the world's first home therapy that is clinically proven to increase engagement and improve relaxation in autistic children with elevated Delta band brain activity.

NTI General Information +

ASX Code NTI
Website http://www.neurotechinternational.com
Industry/Sector Health Care Equipment
Market Cap ($M) 88
NTI Share Price $0.096
Day High $0.100
Day Low $0.093
Last Close $0.095
NTI Share Price Movement $0.00 ( 1.05% )
Prices as at 16:40, 19 Apr 2024
+Security prices are delayed by at least 20 minutes and are indicative only.
Upsell Banner

NTI Related Research

Neurotech International Limited (NTI) Upcoming Dividends & Yields

There are no dividends for Neurotech International Limited (NTI). Please use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Neurotech International Limited (NTI) Recent ASX Announcements

Headline Annoucement date/time+ Price at announcement+ Current price+ Price 7D Avg Gain/Loss
Initial Director's Interest Notice 19 Apr 2024 12:39PM $0.095 $0.096 $0.105 risen by 1.05%
Final Director's Interest Notice 19 Apr 2024 12:35PM $0.095 $0.096 $0.105 risen by 1.05%
Proposed issue of securities - NTI 19 Apr 2024 9:23AM $0.095 $0.096 $0.105 risen by 1.05%
  • + Company announcements and prices are delayed by at least 20 minutes. Prices are indicative only.

See all ASX announcements from Neurotech International Limited (NTI) or use our ASX Announcements tool to search for announcements across all ASX-listed securities.

NTI Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2023A -$7.79 -$1.00 104.20% 0.00 0.00 0.00% 0.0%
2022A -$3.36 -$0.50 -68.20% 0.00 0.00 0.00% 0.0%
2021A -$7.43 -$1.50 36.00% 0.00 0.00 0.00% 0.0%

NTI Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2021 A 2022 A 2023 A 2021 A 2022 A 2023 A 2021 A 2022 A 2023 A
Cochlear (COH) $20,843M 0.1063 0.3407 0.1157 68.7225 51.2596 45.9426 1.04% 1.32% 1.52%
Fisher & Paykel Hlth (FPH) $14,366M -0.3337 0.0134 0.3118 61.1180 60.3089 45.9727 1.66% 1.33% 1.47%
Neurotech International (NTI) $92M 1.0417 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
ResMed (RMD) $17,929M 0.1879 0.0960 0.1089 31.3130 28.5714 25.7650 0.71% 0.95% 1.05%

NTI Market Comparison

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.00 0.00 21.10 0.00
Market 0.53 15.30 1.11 1.01
Sector 0.84 33.30 2.35 2.42

NTI Directors

Name Position Start Date
Dr Thomas (Tom) Duthy Executive Director 1 Sep 2022
Mr Winton William Willesee Non-Executive Director 16 Apr 2019
Mr Gerald Quigley Non-Executive Director, Director of Public Relations 7 Jul 2022
Mr Mark Davies Non-Executive Director, Non-Executive Chairman 16 Apr 2019

Neurotech International Limited (NTI) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
29 Jan 2024 DUTHY, Thomas (Tom) Buy Indirect Shares 340,000 $0.091 $30,820.000
30 Nov 2023 DAVIES, Mark Exercise Options 2,000,000 $0.038 $76,000.000
30 Nov 2023 DAVIES, Mark Buy Options 2,000,000 $0.038 $76,000.000

See all changes in directors' interest & trades for Neurotech International Limited (NTI) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

NTI Management

Name Position
Erlyn Dawson Company Secretary
Alessandra Gauvin Joint Company Secretary

NTI Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Neurotech International Limited (NTI). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding Name
36,402,227 (5.01%) Merchant Funds Management Pty Ltd

NTI Calendar of Events

Date Event
25 February 2025 Report (Interim)
20 September 2024 Report (Annual)
28 August 2024 Report (Annual)
28 August 2024 Report (Prelim)

FAQs about Neurotech International Limited (NTI)

Neurotech International Limited's (NTI) current share price is $0.10. This constitutes a price movement of 8.57% when compared to the share price 7 days ago and is -20% below NTI's 12-month high of $0.12 per share. Prices are delayed by at least 20 minutes.

Relative to the previous close share price of $0.10, Neurotech International Limited's (NTI) current share price of $0.10 constitutes a movement of $0.00 or 1.05%. Neurotech International Limited's (NTI) share price movement is -8.57% when compared to 7 days ago and is -20% below NTI's 52-week high of $0.12.

Neurotech International Limited's (NTI) 52-week high is $0.12 which was reached on 23 Feb 2024. Relative to this, NTI's current share price of $0.10 constitutes a -$0.02 or -20% drop since that high of $0.12 per NTI share.

Neurotech International Limited's (NTI) 52-week low is $0.03 which was reached on 23 Jun 2023. Relative to this, NTI's current share price of $0.10 constitutes a $0.06 or 190.91% gain since that low of $0.03 per NTI share.

Over the last 12 months, Neurotech International Limited (NTI) has a daily average trading volume of 1,020,022 NTI shares per day.

Neurotech International Limited (NTI) has a current dividend yield of n/a this year. Last year's dividend yield was 0%. The dividend yield for NTI is a ratio that tells you the percentage of Neurotech International Limited's (NTI) share price that it pays out in dividends each year.

Neurotech International Limited (NTI) will release its next Annual Report on 20 September 2024. Neurotech International Limited's (NTI) last annual report was released on 22 Sep 2023. Click here to view Neurotech International Limited's (NTI) last annual report.

Neurotech International Limited (NTI) is classified as Health Care. Other companies in this sector include CSL Limited (CSL), ResMed Inc. (RMD), Cochlear Limited (COH), and Fisher & Paykel Healthcare Corporation Limited (FPH).

The price-to-earnings (P/E) ratio for Neurotech International Limited (NTI) is 0. The price-to-earnings ratio, also known as P/E ratio, P/E, or PER, is the ratio of Neurotech International Limited's (NTI) share price to its earnings per NTI share.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© 2017 Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.